PPD in the News

PPD® Laboratories has developed five new molecular, serology and functional assays designed expressly for COVID-19 vaccine and therapy development programs.

Robert King, Hunter Everton and Philip Bartle discuss how to tackle data reporting challenges while significantly reducing both time and cost.

Panteli Theocharous discusses the three major themes that have emerged in 2020 in response to the sharpened focus on advancing the development of CAR-T therapies.

Brent Denton, John Bak and Jonathon Salsbury discuss how light obscuration testing is the preferred method of sub-visible particle quantification, but is not suitable for every preparation.

PPD is extending its digital clinical trial offering to support its biopharma clients' R&D as life science companies continue to find workarounds on trial delays.

Accelerated Enrollment Solutions has introduced a new program to help biopharmaceutical companies maintain business continuity during the global COVID-19 pandemic.

Accelerated Enrollment Solutions and Science 37 are collaborating to recruit and enroll clinical trial participants who live beyond the geographic location of traditional research sites.

Mel Formica, global head, value and development consulting, Evidera, discusses the challenges regulators face as they seek to understand the acceptability of cutting-edge real-world data.

Kristopher Garibay, Eric Olson and Jonathon Salsbury of PPD® Laboratories GMP Lab discuss how the use of particle size distribution profiles by laser diffraction is a common analytical technique utilized across multiple industries.